Abstract 457P
Background
Cancer patients have a significantly higher risk of developing venous thromboembolism (VTE) compared to the general population. But there are no data on the management of cancer associated VTE at the end of life and no guidance when to stop anticoagulation for the imminent death in hospice care.
Methods
We retrospectively reviewed 153 VTE patients with advanced cancer who were treated with anticoagulation in our hospital from January 2016 to December 2022.
Results
Total 153 patients managed with anticoagulation for the treatment and secondary prevention for cancer associated VTE were enrolled. The median age of patients with 66 years and 69% of patients were female. The median duration of treatment with anticoagulation was 92.3 days. 42% of patients were receiving prophylactic anticoagulation, most frequently low molecular weight heparin. Of these patients, 47 patients continued anticoagulation therapy until death, 22 patients up to 7 days prior to death, 14 patients up to 28 days to 8 days and 15 patients over 1 month. Clinically relevant non-major bleeding was recorded 8 patients. However, bleeding rates increased closer impending death with 6 patients of bleeding in the last 7 days of life. No data were recorded suggestive of recurrence VTE or major bleeding. Despite specialized palliative consultation, at the time of death 30% of patients were still on prophylactic anticoagulation.
Conclusions
The majority of advanced cancer patients with VTE were managed with anticoagulation up to or within days of death in real world. Patients with poor performance status and short prognosis are unlikely to benefit from anticoagulation. Given the absence of guidelines about the use of anticoagulation in terminal cancer patients, it should be an early and multidisciplinary decision. It will be a strategy to improve a rational policy of anticoagulation and to prevent bleeding complication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract